Effect of 5-Campestenone (24-methylcholest-5-en-3-one) on Zucker diabetic fatty rats as a type 2 diabetes mellitus model.
We examined the therapeutic effects of dietary exposure to 5-campestenone (24-methylcholest-5-en-3-one), an enone derivative of campesterol, in Zucker diabetic fatty (ZDF) rats, an animal model of type 2 diabetes mellitus. Dietary 0.6 % exposure to 5-campestenone caused marked reduction in hemoglobin A1c (HbA1c), plasma total cholesterol, triglycerides and non esterified fatty acid (NEFA). In particular, plasma triglyceride levels were reduced in the 0.6 % 5-campestenone-fed group to about 25 % of that in the control group. In the oral glucose tolerance test (OGTT) at three and seven weeks after the beginning of treatment, 5-campestenone limited the rise of blood glucose levels by oral administration of glucose dose-dependently. Amounts of adipose tissue in the retroperitoneum and periepididymal area as well as abdominal subcutaneous fat were significantly decreased in animals fed 0.6 % 5-campestenone. The blood leptin concentration on the final day of feeding was significantly in animals administered 5-campestenone. No obvious anomaly due to consumption of 5-campestenone was detected in necropsy or clinical observations.
Konno
R
R
Technoflora Co. and Synthetic Organic Chemistry Laboratory, RIKEN, Japan. rkonno@postman.riken.go.jp
Kaneko
Y
Y
Suzuki
K
K
Matsui
Y
Y
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002783:Cholestenones / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004032:Diet; D004195:Disease Models, Animal; D005951:Glucose Tolerance Test; D006441:Hemoglobin A / Q000032:analysis; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000097:blood; D051381:Rats; D011924:Rats, Zucker
C463760:5-campestenone; D001786:Blood Glucose; D002783:Cholestenones; D020738:Leptin; D008055:Lipids; D006441:Hemoglobin A